Single Pass Albumin Dialysis-A Dose-Finding Study to Define Optimal Albumin Concentration and Dialysate Flow.
Several artificial liver support concepts have been evaluated both in vitro and clinically. Single pass albumin dialysis (SPAD) has shown to be one of the most simple approaches for removing albumin-bound toxins and water-soluble substances. Being faced with acute liver failure (ALF) in everyday practice encouraged our attempt to define the optimal conditions for SPAD more precisely in a standardized experimental setup. Albumin concentration was adjusted to either 1%, 2%, 3%, or 4%, while the flow rate of the dialysate was kept constant at a speed of 700 mL/h. The flow rate of the dialysate was altered between 350, 500, 700, and 1000 mL/h, whereas the albumin concentration was continuously kept at 3%. This study revealed that the detoxification of albumin-bound substances could be improved by increasing the concentration of albumin in the dialysate with an optimum at 3%. A further increase of the albumin concentration to 4% did not lead to a significant increase in detoxification. Furthermore, we observed a gradual increase of the detoxification efficiency for albumin-bound substances, from 350 mL/h to 700 mL/h (for bilirubin) or 1000 mL/h (for bile acids) of dialysate flow. Water-soluble toxins (ammonia, creatinine, urea, uric acid) were removed almost completely, regardless of albumin concentration or flow rate. In conclusion, this study confirmed that SPAD is effective in eliminating albumin-bound as well as water-soluble toxins using a simulation of ALF. Furthermore, this project was successful in evaluating the most effective combination of albumin concentration (3%) and dialysate flow (700 mL/h-1000 mL/h) in SPAD for the first time.
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Rosa Bianca
RB
Schmuck
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Gesa-Henrike
GH
Nawrot
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Panagiotis
P
Fikatas
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Anja
A
Reutzel-Selke
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Johann
J
Pratschke
General, Visceral and Transplantation Surgery, & Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Igor Maximilian
IM
Sauer
D015314:Dialysis Solutions / Q000378:metabolism / Q000627:therapeutic use*; D004867:Equipment Design; D006801:Humans; D017114:Liver Failure, Acute / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D019164:Liver, Artificial; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism / Q000627:therapeutic use*; D016060:Sorption Detoxification / Q000295:instrumentation / Q000379:methods*
D015314:Dialysis Solutions; D012709:Serum Albumin
Acute liver failure; Albumin dialysis; Artificial liver support; Extracorporeal liver support